You are about to leave www.astellas.com and enter a third-party website. Astellas is not responsible for the content or services on the third-party website.
Would you like to continue?
Astellas is committed to providing timely and accurate information about our business, science and products. This section offers local resources for investors, journalists and media professionals. Global news and resources can be viewed here. If you are not an investor or journalist, click here.
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-基于验证性EV-301试验总生存期结果的常规批准...
Read more about 美国FDA授予PADCEV® （enfortumab vedotin-ejfv）常规批准及扩展适应症：用于治疗局部晚期或转移性尿路上皮癌患者
–八篇摘要，涵盖FLT3突变阳性的急性髓性白血病、患者治疗偏好以及在难治性血液肿瘤上的临床应用。...
Read more about 在欧洲血液学协会年会（EHA2021），八篇新研究成果反映了安斯泰来对急性髓性白血病的承诺
安斯泰来3月提交的新药申请是用于治疗经抗癌药物治疗后进展的局部晚期或转移性尿路上皮癌...
恩扎卢胺是目前唯一一款获得欧盟委员会批准治疗三类晚期前列腺癌的口服药物。...
Follow China news
